# Vimta Labs (NSE: VIMTALABS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VIMTALABS · Pivot · prices to 22 Oct 2026

Vimta Labs (NSE: VIMTALABS) closed at ₹495.55 on 22 Oct 2026, up 2.15% on the day. With a market capitalisation of ₹2,214 Cr, it ranks 1101st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

At its last close the stock traded at 28.5× trailing earnings, against a return on equity of 12.8% in FY24. Over the past year the share price has fallen 28.3%. Its 52-week range is ₹376.05 (30 Mar 2026) to ₹735.00 (3 Nov 2025); the last close is 32.6% below the high. In Q3 FY25, the quarter ended 31 Dec 2024, revenue was ₹90 Cr (+10.1% year on year) and net profit ₹22 Cr (+112.2%), on a consolidated basis. Promoters held 35.67% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹495.55 |
| Market cap | ₹2,214 Cr |
| P/E (trailing) | 28.5 |
| ROE | 12.8% (FY24) |
| ROCE | 16.4% (FY24) |
| Debt to equity | 0.06 |
| 52-week high | ₹735.00 (3 Nov 2025) |
| 52-week low | ₹376.05 (30 Mar 2026) |
| 1-year return | −28.3% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q3 FY25 | ₹90 Cr | +10.1% | ₹22 Cr | +112.2% | ₹9.65 |
| Q2 FY25 | ₹85 Cr | +15.4% | ₹15 Cr | +140.9% | ₹6.88 |
| Q1 FY25 | ₹82 Cr | −2.1% | ₹12 Cr | +0.7% | ₹5.54 |
| Q4 FY24 | ₹80 Cr | −2.6% | ₹12 Cr | −2.6% | ₹5.58 |
| Q3 FY24 | ₹82 Cr | +5.6% | ₹10 Cr | −1.1% | ₹4.57 |
| Q2 FY24 | ₹73 Cr | −8.1% | ₹6 Cr | −52.1% | ₹2.85 |
| Q1 FY24 | ₹83 Cr | +5.5% | ₹12 Cr | +1.3% | ₹5.51 |
| Q4 FY23 | ₹82 Cr | +10.4% | ₹13 Cr | +7.2% | ₹5.73 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY24 | ₹318 Cr | ₹41 Cr |
| FY23 | ₹318 Cr | ₹48 Cr |
| FY22 | ₹278 Cr | ₹41 Cr |
| FY21 | ₹211 Cr | ₹21 Cr |
| FY20 | ₹181 Cr | ₹7 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 35.67%
- Foreign institutions: 4.42%
- Domestic institutions: 0.37%
- Non-institutions: 59.55%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Fredun Pharmace](https://app.pivotnow.in/stock/FREDUN) | ₹1,376.10 | ₹2,276 Cr | 22.5 | — |
| [Dishman Carbogen Amcis](https://app.pivotnow.in/stock/DCAL) | ₹141.95 | ₹2,226 Cr | 22.8 | — |
| [Medi Assist Healthcare Services](https://app.pivotnow.in/stock/MEDIASSIST) | ₹291.75 | ₹2,179 Cr | 24.1 | — |
| [Syncom Formulations (India)](https://app.pivotnow.in/stock/SYNCOMF) | ₹22.83 | ₹2,146 Cr | 28.2 | — |
| [Indoco Remedies](https://app.pivotnow.in/stock/INDOCO) | ₹230.55 | ₹2,128 Cr | — | — |
| [Panacea Biotec](https://app.pivotnow.in/stock/PANACEABIO) | ₹335.85 | ₹2,057 Cr | — | — |

## Questions and answers

### What is the share price of Vimta Labs today?

Vimta Labs (NSE: VIMTALABS) last closed at ₹495.55 on 22 Oct 2026. Its 52-week high is ₹735.00 and its 52-week low is ₹376.05.

### What is the market cap of Vimta Labs?

Vimta Labs' market capitalisation is ₹2,214 Cr (₹2,214 Cr) at the 22 Oct 2026 close, ranking 1101st among the NSE companies Pivot tracks.

### What is the P/E ratio of Vimta Labs?

Vimta Labs trades at a trailing P/E of 28.5. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 24.1.

### What is the ROE and ROCE of Vimta Labs?

Return on equity was 12.8% in FY24 and return on capital employed was 16.4% in FY24 (consolidated figures).

### Is Vimta Labs a debt-free company?

No. Vimta Labs' debt-to-equity ratio was 0.06 in FY24, with total debt of ₹9 Cr.

### What were Vimta Labs' latest quarterly results?

For Q3 FY25 (quarter ended 31 Dec 2024), Vimta Labs reported revenue of ₹90 Cr, +10.1% year on year, and net profit of ₹22 Cr, +112.2% year on year.

### How has Vimta Labs stock performed over the last year?

Vimta Labs' share price has fallen 28.3% over the past year, −14.9% over three months and −19.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Vimta Labs?

As of 30 Jun 2026: promoters 35.67%, foreign institutions 4.42%, domestic institutions 0.37%, non-institutions 59.55%.

### Who are Vimta Labs' competitors?

The listed Pharma & Healthcare companies closest to Vimta Labs by market cap are Fredun Pharmace, Dishman Carbogen Amcis, Medi Assist Healthcare Services, Syncom Formulations (India), Indoco Remedies and Panacea Biotec.

### Is Vimta Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Vimta Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIMTALABS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.